Breakthroughs in Anemia and Iron Management
October 22, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
Oral Abstract Session
Breakthroughs in Anemia and Iron Management
October 22, 2020 | 05:00 PM - 07:00 PM
Location: Simulive
Session Description
Oral Abstract Session
Learning Pathway(s)
- Bone and Mineral Metabolism
Moderators
- Steven Fishbane, MD
- Jay B. Wish, MD, FASN
Presentations
- Global Phase 3 Clinical Trials of Vadadustat vs. Darbepoetin Alfa for Treatment of Anemia in Patients with Dialysis-Dependent CKD
05:00 PM - 07:00 PM
Kai-Uwe Eckardt, MD
Kai-Uwe Eckardt, MD
Kai-Uwe Eckardt is Professor of Medicine and Head of the Department of Nephrology and Medical Intensive Care at the Charité in Berlin, Germany. Prior to taking this position in April 2017 he was Chair of Nephrology and Hypertension at the University of Erlangen-Nürnberg, where he also served as Vice Dean for Research and International Affairs.
Dr. Eckardt's major scientific interests lie in the molecular mechanisms and relevance of oxygen sensing and the development of acute and chronic renal injury. He chaired a Collaborative Research Centre (CRC) on kidney injury at the University of Erlangen-Nürnberg and is currently vice spokesperson of the CRC 1365 "Renoprotection" at the Charité. He is also principal investigator of the German Chronic Kidney Disease (GCKD) study, the largest CKD cohort study worldwide. Dr. Eckardt is a member of review panels of the German Research Foundation and has served on several international scientific advisory boards. He has also served in various capacities for international organizations, including terms as council member of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), councillor and executive councillor of the International Society of Nephrology (ISN), chair of the ISN Forefront Committee, program chair of the World Congress of Nephrology 2009 and 2017 and founding executive committee member and past co-chair of the organization Kidney Disease: Improving Global Outcomes (KDIGO).
Global Phase 3 Clinical Trials of Vadadustat vs. Darbepoetin Alfa for Treatment of Anemia in Patients with Dialysis-Dependent CKD
October 22, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Roxadustat for the Treatment of Anemia in CKD Patients Not on Dialysis (NDD): A Phase 3, Randomized, Open-Label, Active-Controlled Study
05:00 PM - 07:00 PM
Jonathan Barratt, MBChB, PhD
Jonathan Barratt, MBChB, PhD
I lead the Renal Research Group within the College of Life Sciences, University of Leicester. My research interests span a range of areas across renal medicine and include glomerular disease, multi-system renal disease and complications of chronic kidney disease, in particular renal associated anaemia. I am the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and a member of the steering committee for the International IgA Nephropathy Network. I am Chief Investigator for a number of international randomised controlled clinical trials, have attended both the FDA and EMA as an advisor for new therapies in IgA nephropathy, and am a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgA Nephropathy Workgroup. I am an Editorial Board member for Kidney International and Clinical Journal of the American Society of Nephrology and sit on the Kidney Research UK Grants Committee.
Roxadustat for the Treatment of Anemia in CKD Patients Not on Dialysis (NDD): A Phase 3, Randomized, Open-Label, Active-Controlled Study
October 22, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Roxadustat Treatment Results in Consistent Improvements in Hemoglobin (Hb) vs. Placebo: An Analysis of Three Multinational Randomized Clinical Trials in Patients with Non-Dialysis-Dependent CKD (NDD-CKD)
05:00 PM - 07:00 PM
Roberto Pecoits-Filho, MD, PhD, FASN
Roberto Pecoits-Filho, MD, PhD, FASN
Roxadustat Treatment Results in Consistent Improvements in Hemoglobin (Hb) vs. Placebo: An Analysis of Three Multinational Randomized Clinical Trials in Patients with Non-Dialysis-Dependent CKD (NDD-CKD)
October 22, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Roxadustat Treatment of Anemia in Non-Dialysis-Dependent CKD Is Not Influenced by Iron Status
05:00 PM - 07:00 PM
Robert Provenzano, MD, FASN
Robert Provenzano, MD, FASN
Robert Provenzano, MD, FACP, FASN, is a clinical professor of medicine at Wayne State University School of Medicine in Detroit, where he earned his medical degree. He completed his fellowship training at Henry Ford Hospital and served as the chief of the section of nephrology, hypertension and transplantation and director of nephrology research at St. John Hospital and Medical Center in Detroit.
Roxadustat Treatment of Anemia in Non-Dialysis-Dependent CKD Is Not Influenced by Iron Status
October 22, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Roxadustat Is Not Associated with an Increased Risk of Neoplasm in Patients with CKD and Anemia
05:00 PM - 07:00 PM
Daniel W. Coyne, MD
Daniel W. Coyne, MD
Daniel W. Coyne, MD, is Professor of Medicine in the Division of Nephrology at Washington University School of Medicine in St. Louis, Missouri. He is the Medical Director of the University’s academic dialysis facility, the Chromalloy American Kidney Center. He has been involved in trials of agents to treat anemia since 1998. His research interests include the risks and benefits of erythropoiesis-stimulating agents, IV iron, and HIF-PH Inhibitors in patients with the anemia of CKD.
Roxadustat Is Not Associated with an Increased Risk of Neoplasm in Patients with CKD and Anemia
October 22, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Hemoglobin (Hb) Correction with Roxadustat Is Associated with Improved Iron Homeostasis in Patients with Dialysis-Dependent CKD (DD-CKD)
05:00 PM - 07:00 PM
Pablo E. Pergola, MD, PhD
Pablo E. Pergola, MD, PhD
Hemoglobin (Hb) Correction with Roxadustat Is Associated with Improved Iron Homeostasis in Patients with Dialysis-Dependent CKD (DD-CKD)
October 22, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Adverse Event Rates Are Higher Post-Transfusion vs. Overall Follow-up and Independent of Background Anemia Treatment in Patients with CKD
05:00 PM - 07:00 PM
Robert Provenzano, MD, FASN
Robert Provenzano, MD, FASN
Robert Provenzano, MD, FACP, FASN, is a clinical professor of medicine at Wayne State University School of Medicine in Detroit, where he earned his medical degree. He completed his fellowship training at Henry Ford Hospital and served as the chief of the section of nephrology, hypertension and transplantation and director of nephrology research at St. John Hospital and Medical Center in Detroit.
Adverse Event Rates Are Higher Post-Transfusion vs. Overall Follow-up and Independent of Background Anemia Treatment in Patients with CKD
October 22, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Renoprotective Effects of Ferric Citrate in a Mouse Model of CKD
05:00 PM - 07:00 PM
Mark R. Hanudel, MD, MS, FASN
Mark R. Hanudel, MD, MS, FASN
I am an Assistant Professor of Pediatrics at UCLA, in the Division of Nephrology. I completed my undergraduate studies at Yale University, medical degree at Harvard Medical School, pediatric residency at UCLA, and pediatric nephrology fellowship at UCLA. My research focuses on studying the interrelated complications of chronic kidney disease, including iron dysregulation, anemia, disordered bone and mineral metabolism, and heart disease. My mentors are Drs. Isidro Salusky, Tomas Ganz, and Elizabeta Nemeth. I am currently supported by an American Society of Nephrology Carl W. Gottschalk Research Scholar Grant.
Renoprotective Effects of Ferric Citrate in a Mouse Model of CKD
October 22, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Regional Variation of Erythropoietin-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
05:00 PM - 07:00 PM
Ajay K. Singh, MD
Ajay K. Singh, MD
Dr Ajay Singh is a member of the Renal Division at the Brigham and Women's Hospital and faculty and Senior Associate Dean for Postgraduate Medical Education at Harvard Medical School. Dr. Singh was PI for the CHOIR Study, a member of the executive committee for the TREAT study and DRIVE study. Currently, he chairs the executive steering committee for the ASCEND Clinical Trial Program sponsored by GSK. The ASCEND program includes two large global cardiovascular outcome trials in maintenance dialysis and non-dialysis CKD patients and one smaller trial in incident dialysis patients that aims to test the efficacy and safety of the daprodustat, a novel PHI.
Regional Variation of Erythropoietin-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
October 22, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- A Real-World Longitudinal Analysis of Anemia Treatment Prescriptions in Non-Dialysis-Dependent CKD Patients, a CKDopps Study
05:00 PM - 07:00 PM
Marcelo Lopes, MD, PhD, MPH
Marcelo Lopes, MD, PhD, MPH
Nephrologist, ISN Scholar. Epidemiologist with MPH through the School of Public Health, University of Michigan. Research Analyst, Arbor Research Collaborative for Health.
A Real-World Longitudinal Analysis of Anemia Treatment Prescriptions in Non-Dialysis-Dependent CKD Patients, a CKDopps Study
October 22, 2020 | 05:00 PM - 07:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
